Volume 16, Issue 3 (May & June 2025)
BCN 2025, 16(3): 619-632 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Saffarpour S, Mehraz A, Sadeghi Tehran P, Nasirinezhad F. Impact of Genotropin on Oxidative Stress, Glutamate, and Nitric Oxide Pathways in a Rat Model of Peripheral Neuropathy. BCN 2025; 16 (3) :619-632
URL: http://bcn.iums.ac.ir/article-1-2913-en.html
URL: http://bcn.iums.ac.ir/article-1-2913-en.html
1- Department of Orthopedics, Bone and Joint Reconstruction Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
4- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. & Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. & Center for Experimental and Comparative Study, Iran University of Medical Sciences, Tehran, Iran.
2- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
4- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. & Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. & Center for Experimental and Comparative Study, Iran University of Medical Sciences, Tehran, Iran.
Abstract:
Introduction: Genotropin, a recombinant human growth hormone (GH), has been proposed as a potential repositioning drug to treat neurological disorders. However, its efficacy in managing neuropathic pain remains unclear. This study aimed to evaluate the analgesic effects of Genotropin and investigate its potential mechanisms of action.
Methods: Two weeks after chronic constriction injury (CCI) of the sciatic nerve, adult male rats were randomly assigned to three main groups: Control, vehicle (normal saline [NS]), and treatment. The treatment group received Genotropin at doses of 0.3 and 0.6 mg/kg, either alone or in combination with L-arginine, L-NAME, or glutamate (n=8 per group). Pain-related behaviors were assessed using Von Frey filaments, the plantar test, and the Randall–Selitto test. Blood samples were collected to analyze oxidative and antioxidative markers.
Results: Genotropin significantly reduced mechanical allodynia (P<0.05, F=2.7) and mechanical (P<0.01, F=3.4) and thermal hyperalgesia (P<0.001, F=2.5). Pretreatment with 0.3 mg/kg GH abolished the pronociceptive effects of L-arginine (500 mg/kg) and glutamate (1000 nmol) (P<0.01; F=2, F=3) while enhancing the antinociceptive effect of L-NAME (P<0.05, F=2.8). GH also significantly reduced lipid peroxidation (P<0.01, F=3.7) and restored levels of glutathione, glutathione peroxidase (GPx), and superoxide dismutase (SOD) (P<0.01; F=11, F=10.52, F=5, respectively). Additionally, catalase (CAT) levels were significantly increased (P<0.01, F=5).
Conclusion: These results suggest that exogenous GH alleviates neuropathic pain and enhances antioxidant defenses in a model of peripheral neuropathic pain. The involvement of glutamate and nitric oxide (NO) pathways in GH’s antinociceptive effects was also demonstrated. Therefore, Genotropin holds potential as a repositioned therapeutic agent for treating neuropathic pain.
Methods: Two weeks after chronic constriction injury (CCI) of the sciatic nerve, adult male rats were randomly assigned to three main groups: Control, vehicle (normal saline [NS]), and treatment. The treatment group received Genotropin at doses of 0.3 and 0.6 mg/kg, either alone or in combination with L-arginine, L-NAME, or glutamate (n=8 per group). Pain-related behaviors were assessed using Von Frey filaments, the plantar test, and the Randall–Selitto test. Blood samples were collected to analyze oxidative and antioxidative markers.
Results: Genotropin significantly reduced mechanical allodynia (P<0.05, F=2.7) and mechanical (P<0.01, F=3.4) and thermal hyperalgesia (P<0.001, F=2.5). Pretreatment with 0.3 mg/kg GH abolished the pronociceptive effects of L-arginine (500 mg/kg) and glutamate (1000 nmol) (P<0.01; F=2, F=3) while enhancing the antinociceptive effect of L-NAME (P<0.05, F=2.8). GH also significantly reduced lipid peroxidation (P<0.01, F=3.7) and restored levels of glutathione, glutathione peroxidase (GPx), and superoxide dismutase (SOD) (P<0.01; F=11, F=10.52, F=5, respectively). Additionally, catalase (CAT) levels were significantly increased (P<0.01, F=5).
Conclusion: These results suggest that exogenous GH alleviates neuropathic pain and enhances antioxidant defenses in a model of peripheral neuropathic pain. The involvement of glutamate and nitric oxide (NO) pathways in GH’s antinociceptive effects was also demonstrated. Therefore, Genotropin holds potential as a repositioned therapeutic agent for treating neuropathic pain.
Keywords: Growth hormone (Genotropin), Neuropathic pain, Oxidative factors, Nitric oxide (NO), Glutamate
Type of Study: Original |
Subject:
Cellular and molecular Neuroscience
Received: 2024/04/6 | Accepted: 2024/12/4 | Published: 2025/05/29
Received: 2024/04/6 | Accepted: 2024/12/4 | Published: 2025/05/29
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
